Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Pipetting a DNA (deoxyribonucleic acid) sample into a multiwell plate with DNA information in the background

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

June 2, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 47

Close-up of pipette releasing clear liquid droplet into a petri dish with DNA sequencing image in background.

May 16, 2025 Blog

100 Days In: FDA Updates and Trends to Watch

artificial intelligence machine learning big data concept

April 17, 2025 Blog

Preparing for the European Health Data Space — Opportunities and Challenges for Europe’s Digital Future

March 5, 2025 Blog

HHS Issues Policy Statement to Expand Use of Rulemaking Without Notice and Comment

Digitally rendered gel capsule filled with multicolor spheres.

October 6, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 56

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.

October 2, 2025 Podcast

Episode 103 — Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

The largest drug pricing conference of the year just concluded in Chicago. Join the Latham team to discuss key themes and highlights, including most favored nation pricing considerations, bona fide service fee changes, and 340B program developments.

October 1, 2025 Blog

Navigating the 2025 US Government Shutdown

September 25, 2025 Client Alert

Bipartisan Bill Aims to Expand Sunshine Act Reporting for Manufacturers

September 24, 2025 Client Alert

FDA Begins Crackdown on Direct-to-Consumer Pharmaceutical Advertising

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

Our Archive

3d rendering Neon Colored wavy Abstract background, futuristic texture design for Business science and Technology advertising

October 7, 2025 Our Work

Latham & Watkins Advises Press Ganey Forsta in US$6.75 Billion Acquisition by Qualtrics

Multidisciplinary team represents the experience measurement and data analytics company in the transaction.

Medical professionals performing surgery in an operating room.

October 6, 2025 Our Work

Latham & Watkins Advises Oath Surgical on US$24 Million Series A to Build the First Surgeon-Owned, AI-Powered Surgical System

Firm represents the surgical technology company in the funding round to scale a national network of high-tech surgery centers.

October 6, 2025 Our Work

Latham Advises MediWound on US$30 Million Registered Direct Offering of Ordinary Shares

September 30, 2025 Our Work

Latham & Watkins Advises Merus in US$8 Billion Acquisition by Genmab

September 30, 2025 Our Work

Latham & Watkins Advises Crystalys Therapeutics in US$205 Million Series A Financing

Soft focus bokeh light effects over a rippled, blue water background in the pool.

September 22, 2025 Recognition

Litigators of the Week Winner: Truce With Generic Makers Over Rinvoq Sends AbbVie Share Price to New High

A Latham team led by David Frazier won the “Litigators of the Week” competition, alongside co-counsel at Covington, for their outstanding representation of AbbVie in securing the latest of five patent litigation settlements with generic makers that are set to protect its blockbuster immunology drug Rinvoq until 2037.